Skip to content
DataLookout
Menu

LINKER-AL1NCT07901725

Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to 7 years
Severity of TEAEs
Timeframe: Up to 7 years
Occurrence of Adverse Events of Special Interest (AESI)
Timeframe: Up to 7 years
Severity of AESI
Timeframe: Up to 7 years
Occurrence of Serious Adverse Events (SAEs)
Timeframe: Up to 7 years
Severity of SAEs
Timeframe: Up to 7 years
Achievement of Hematologic Complete Response (HemCR) per International Society of Amyloidosis (ISA) response criteria as determined by Blinded Independent Review Committee (BIRC)
Timeframe: Up to 7 years

Secondary (31)

Occurrence and timing of grade 2 or 3 Cytokine Release Syndrome (CRS)
Major Organ Deterioration-Progression-Free Survival (MOD-PFS) as determined by BIRC per modified ISA criteria
Overall Survival (OS)
Occurrence of a graded cardiac response in participants who are cardiac response evaluable at trial entry
Time to cardiac response in participants who are cardiac response evaluable at trial entry
Show 26 moreShow less
Occurrence of a graded renal response in participants who are renal response evaluable at trial entry
Time to first renal response in participants who are renal response evaluable at trial entry
Achievement of Very Good Partial Response or better (≥VGPR) as assessed by BIRC per ISA response criteria
Achievement of Partial Response or better (≥PR) as assessed by BIRC per ISA response criteria
Duration of Response (DOR) per ISA response criteria
Duration of HemCR per ISA response criteria
Time to Next Treatment (TTNT)
Achievement of HemCR as assessed by the BIRC per ISA response criteria
Occurrence of TEAEs
Severity of TEAEs
Occurrence of AESI
Severity of AESI
Occurrence of SAEs
Severity of SAEs
Change from baseline in Short Form Health Survey 36 version 2 (SF-36v2) General Health (GH) scale
Change from baseline in EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Scale (VAS)
Change from baseline in SF-36v2 Physical Component Score (PCS)
Change from baseline in SF-36v2 Physical Functioning (PF) scale
Change from baseline in SF-36v2 Role Physical (RP) scale
Change from baseline in FACIT (Functional Assessment of Chronic Illness Therapy)-Dyspnea Part I (Dyspnea Severity Scale)
Change from baseline in FACIT-Fatigue scale
Proportion of time with high side-effect bother during treatment per Functional Assessment of Chronic Illness Therapy (FACIT) Item Global Physical (GP) 5 score ≥3
Occurrence of high side-effect bother at on-treatment visits per FACIT Item GP5 score ≥3
Concentrations of linvoseltamab in serum
Occurrence of Anti-Drug Antibodies (ADAs) to linvoseltamab
Magnitude of Anti-Drug Antibodies (ADAs) to linvoseltamab

Arms and interventions

LinvoseltamabExperimental
Dara-VcdActive comparator

Drugs: Linvoseltamab, Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone